Research Progress of Antimicrobial Peptides in the Treatment of Diabetic Foot Ulcers

糖尿病足溃疡(DFU)是糖尿病严重的并发症，其慢性感染与组织修复障碍导致高截肢率及治疗成本攀升，给公共卫生体系带来了巨大临床挑战。抗菌肽(AMPs)因其多重抗菌机制及低耐药性风险使其成为治疗的新兴策略。现有研究表明，单一AMPs、联合疗法及相关递送系统均展现出显著疗效，尽管潜力显著，其具体分子机制、临床转化及长期安全性仍需深入探索。未来研究需聚焦于探索AMPs的分子作用机制、开发智能递送系统及大规模临床试验，以突破临床转化瓶颈。本文通过综述近年来国内外关于AMPs及相关治疗策略在促DFU修复中的最新研究进展，为AMPs作为治疗DFU感染的一种潜在的新策略提供理论指导，为改善糖尿病患者的生活质量带来新的治疗策略。Diabetic foot ulcer (DFU), a severe complication of diabetes mellitus, presents a significant clinical challenge to public health systems due to their propensity for chronic infection, impaired tissue repair, high amputation rates, and escalating treatment costs. Antimicrobial peptides (AMPs) have emerged as a promising therapeutic strategy, offering multiple antimicrobial mechanisms and a low risk of resistance. Current research indicates that single AMPs, combination therapies, and relevant delivery systems have shown considerable efficacy. However, despite their potential, the specific molecular mechanisms, clinical translation, and long-term safety of AMPs require further in-depth exploration. Future research should prioritize elucidating the molecular mechanisms of AMPs, developing intelligent delivery systems, and conducting large-scale clinical trials to overcome the barriers to clinical translation. This article reviews recent advancements in AMPs and related therapeutic strategies for promoting DFU repair, both domestically and internationally, aiming to provide theoretical guidance for AMPs as a potential novel treatment for DFU infections and to introduce new therapeutic strategies for enhancing the quality of life for diabetic patients.